Stone medicine will take more than 1 billion anti-inflammatory analgesics is sunny, Hengrui encountered a fierce enemy

Pharmaceutical Network July 9th, the day before, stone medicine European-Italian pharmaceutical industry to copy the 4 categories of reported selazeb capsules in the review status changed to "in the approval", is expected to be approved for listing in the near future and treated as reviewedMinnet data show that in 2019 China's public medical institutions terminal sales of Saixibu capsules of 1.07 billion yuan, Zhengdaqingjiang, Hengrui products have been successfully approved and treated as equalSeloxib is a specific inhibitor developed by Pfizer that inhibits the production of inflammatory prostaglandins by inhibiting cyclooxidase-2 (COX-2) to achieve anti-inflammatory and analgesic effectsThe product, which was first approved by the FDA in 1998, is the world's first selective nonsteroidal anti-inflammatory analgesic, peaking global sales in 2013 and generating sales of $2,918 millionFigure: 2015-2019 Sales of Courise capsules in China's public medical institutions (units: 10,000 yuan)Pfizer's Seleshib capsules were approved by the State Drug Administration to enter the domestic market in October 2012, and were included in the National Health Insurance Directory in 2017, as adrugand use of health insurance, and sales at the terminals of public medical institutions in China in 2019 was 1.07 billion yuan, up 4.4% YoYMinet data show that, in addition to the original research manufacturers, the current domestic two pharmaceutical companies have 2 batches of Selashib capsule production, HengruiPharmaceuticalin December 2019 to take the first imitation of the Selashibu capsule and the first evaluation, Zhengda Tianqing subsidiary IsdaQingjiang products in January 2020 was approved for production and regarded as the same as the evaluation, as the domestic secondTable: The generic seratin capsules reported by the new classification are in the reviewNote: With thefor inclusion in the priority review
in addition to Hengrui and Zhengda Qingjiang, there are 13 pharmaceutical companies to copy 4 categories or import 5.2 categories submitted for listing applications for Seraxib capsules, including Beijing Yabao Bio, Stone Pharmaceutical Group O-Italian Pharmaceuticals, Qingdao Baiyang Pharmaceutical s3enterprises products were included in the priority review, the reasons are the same production line production, apply for domestic listing of generic drugs, stone pharmaceutical group Oyi Pharmaceutical products have entered the administrative approval stage on July 1, 2020, is expected to become the third approved domestic selazeb capsule generic 　　Source: Minnet database Note: statistics as of July 8, if there are omissions, welcome to point!